TY  - GEN
AB  - Immune checkpoint inhibitor (ICI) therapies, such as anti-PD1 and anti-CTLA4, have proved to be clinically effective in numerous malignant diseases due to their ability to maintain immune surveillance of tumors by overriding the mechanisms in which lymphocytes establish peripheral tolerance. However, these therapies act in a systematic manner and thus may lead to autoimmune-like side effects termed immune-related adverse events (irAEs) in many organ systems that can ultimately halt treatment or lead to death. Therefore, understanding the underlying drivers of these irAEs is imperative in ensuring the quality of life and safety of our patients on ICI.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AU  - Doan, Khanh
AU  - Branched, Heather
AU  - Clister, Terri
AU  - Fey, Rosalyn M.
AU  - Garrison, Zach
AU  - Hall, Connor
AU  - Nichols, Rebecca
AU  - Kulkarni, Rajan
DA  - 2024
DO  - 10.6083/bpxhc43623
DO  - doi
ID  - 43623
KW  - Immune Checkpoint Inhibitors
KW  - Exanthema
KW  - Sequence Analysis, RNA
KW  - Lymphocytes
KW  - Skin Diseases
KW  - Single-Cell Gene Expression Analysis
KW  - Exanthema
KW  - immune-related adverse events
KW  - skin rash
KW  - single-cell RNA sequencing
L1  - https://digitalcollections.ohsu.edu/record/43623/files/ResearchWeek.2024.Doan.Khanh.pdf
L2  - https://digitalcollections.ohsu.edu/record/43623/files/ResearchWeek.2024.Doan.Khanh.pdf
L4  - https://digitalcollections.ohsu.edu/record/43623/files/ResearchWeek.2024.Doan.Khanh.pdf
LA  - eng
LK  - https://digitalcollections.ohsu.edu/record/43623/files/ResearchWeek.2024.Doan.Khanh.pdf
N2  - Immune checkpoint inhibitor (ICI) therapies, such as anti-PD1 and anti-CTLA4, have proved to be clinically effective in numerous malignant diseases due to their ability to maintain immune surveillance of tumors by overriding the mechanisms in which lymphocytes establish peripheral tolerance. However, these therapies act in a systematic manner and thus may lead to autoimmune-like side effects termed immune-related adverse events (irAEs) in many organ systems that can ultimately halt treatment or lead to death. Therefore, understanding the underlying drivers of these irAEs is imperative in ensuring the quality of life and safety of our patients on ICI.
PB  - Oregon Health and Science University
PY  - 2024
T1  - Single-cell RNA sequencing analysis or irAE skin rash
TI  - Single-cell RNA sequencing analysis or irAE skin rash
UR  - https://digitalcollections.ohsu.edu/record/43623/files/ResearchWeek.2024.Doan.Khanh.pdf
Y1  - 2024
ER  -